Copyright © Inderes 2011 - present. All rights reserved.
  • Seneste
  • Markeder
    • Aktieoversigt
    • Finanskalender
    • Udbyttekalender
    • Research
    • Artikler
  • InderesTV
  • Forum
  • Om os
    • Fulgte selskaber
    • Team
Analytikerkommentar

Fast comment - NeoDynamics present at The SBI Breast Imaging Symposium

Af Claus ThestrupCEO, Sweden
NeoDynamics

NeoDynamics present at The SBI Breast Imaging Symposium. The company expect to full commercialize NeoNavia and the Pulse technology in US in 2023...

Final data set from NeoDynamics’ PULSE study presented at The SBI Breast Imaging Symposium

The final data set from NeoDynamics’ PULSE study shows favorable safety and efficacy profile of NeoNavia for ultra-sound guided biopsies in the axillary lymph nodes. The data are being presented at The SBI Breast Imaging Symposium this week.

The conference, taking place on May 4-7 2023, at the Gaylord National Resort & Convention Center in National Harbor, Maryland, is the World’s Largest Breast Imaging Conference.
NeoDynamics’ PULSE study is a German prospective multi-center study (ClinicalTrials.gov ID: NCT03975855) designed to document the performance of the NeoNavia biopsy device in the axillary lymph nodes on 138 enrolled patients. Professor Marc Thill, PhD, has been principal investigator. An electronic presentation of his abstract is presented at the Symposium.
The key data of the finalized study are:

  • Success rate for biopsies from the lymph node was 93 % (128/138). (“high success rate”)
  • Hematoma in the axilla occurred in 1.4% (2/138) of patients. Pain in the axilla was reported in 2.9 % (4/138) of patients. (“low rate of adverse events”)
  • The pneumatic pulses promoted control during needle insertion in 89% (123/138) and stabilization of target lesion during needle insertion in 88% (122/138) of patients.
  • 46% (64/138) of patients presented with at least one of four major risk parameters (lymph node diameter <10mm, proximity to blood vessel/muscle/thoracic wall <5mm) (“broad patient cohort”)

The study has demonstrated that pneumatic pulses promoted needle control and stabilization of target lesions during insertion of the needle and that it was possible to obtain multiple samples with a single insertion.

Read full announcement here:

https://www.neodynamics.com/en-gb/press-releases/article/d268b7c5-8cb9-4ef4-9508-d92f9bceed2c/final-data-set-from-neodynamics-pulse-study-presented-at-the-sbi-breast-imaging-symposium

Disclaimer:

HC Andersen Capital receives payment from NeoDynamics for a Digital IR/Corporate Visibility subscription agreement. /ANALYST Claus Thestrup 10:00 AM 05-05-2023.

NeoDynamics AB (publ) is a Swedish Medical Technology Company dedicated to advancing diagnosis and care of breast cancer. The company’s first product NeoNavia®, a new innovative pulse biopsy system for ultrasound guided tissue sampling, is currently being introduced to the market. The biopsy system is built on a patented pulse technology, based on research at the Karolinska Institutet in Sweden.

Læs mere på virksomhedsside
Find os på de sociale medier
  • Inderes Forum
  • Youtube
  • Facebook
  • X (Twitter)
Tag kontakt
  • info@hcandersencapital.dk
  • Bredgade 23B, 2. sal
    1260 København K
Inderes
  • Om os
  • Vores team
  • Karriere
  • Inderes som en investering
  • Tjenester for børsnoterede virksomheder
Vores platform
  • FAQ
  • Servicevilkår
  • Privatlivspolitik
  • Disclaimer
Inderes’ ansvarsfraskrivelse kan findes her. Detaljeret information om hver aktie, der aktivt overvåges af Inderes og HC Andersen Capital, er tilgængelig på de virksomhedsspecifikke sider på Inderes' hjemmeside. © Inderes Oyj. All rights reserved.